15 results
6-K
EX-99.1
SNY
Sanofi
27 Sep 23
Current report (foreign)
6:06am
approach to reduce the environmental footprint of its products. For example, by 2027, the use of plastic in blister packs for all vaccines
6-K
EX-99.1
SNY
Sanofi
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
. This target represents the equivalent of 25 tons of plastic waste.
ESG ratings
B Corp Certification granted to CHC North America in recognition
6-K
EX-99.2
SNY
Sanofi
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
the equivalent of 25 tons of plastic waste.
CSR dashboard as of Q2 2023
Please refer to the Q2 2023 results press release ESG appendix for Sanofi CSR reporting
6-K
EX-99.1
SNY
Sanofi
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am
Planet care
To contribute to better resource conservation, Sanofi plans to remove all plastic blister packs for its syringe vaccines by 2027
6-K
EX-99.1
SNY
Sanofi
28 Jul 22
Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
10:12am
To contribute to better resource conservation, Sanofi plans to remove all plastic blister packs for its syringe vaccines by 2027. In addition
6-K
EX-99.2
afn6ypj34o46olh7yq
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.1
keagoc0
28 Apr 22
Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1
12:16pm
6-K
EX-99.1
bba650ea xzooj
4 Feb 22
Strong 2021 sales and business EPS(1) growth enabling increased investment in R&D
9:56am
6-K
EX-99.1
tjvarf7bc93oine
28 Oct 21
Q3 2021 sales grew double digit to €10.4 billion (up 10.1%) due to strong growth from Dupixent®, Vaccines and CHC
11:19am
6-K
EX-99.1
7jxezm 1dncp8byxw
29 Jul 21
Sales growth accelerated - Full-year guidance raised
9:52am
6-K
EX-99.3
la7o1r
8 Jun 21
Sanofi launches its new global employee share ownership plan
1:31pm
6-K
EX-99.4
a9lk2 lba1naxhfq
13 Apr 21
Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities
2:56pm
- Prev
- 1
- Next